Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9072 Cyclophosphamide (frindovyx) Frindovyx 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2025 Sep 8, 2025 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERÉ‘ Yes 2023 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
Q5129 Bevacizumab-adcd Vegzelma 10mg Immunotherapy Monoclonal Antibody VEGFR No 2023 Mar 17, 2023 In Use
NA Cyclophosphamide Cyclophosphamide oral 50 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 In Use
J2405 Ondansetron Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1991 Jan 1, 1993 In Use
J9064 Cabazitaxel (Sandoz) Cabazitaxel 1mg Chemotherapy Antimitotic Agent Taxane No 2023 Aug 28, 2023 In Use
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
Q5146 Trastuzumab-strf (hercessi) Hercessi 10mg Immunotherapy Monoclonal Antibody HER2 No 2025 Jan 1, 2025 In Use
NA Trilostane Modrastane 60 mg, 120 mg Hormonal Therapy Adrenocortical suppressant Yes 1984 1994 In Use
NA Dabrafenib Tafinlar 50 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
J9047 Carfilzomib Kyprolis 1 mg Chemotherapy Proteasome Inhibitor 20S No 2012 Apr 1, 2014 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct 1, 2019 In Use
J9011 Datopotamab Deruxtecan Datroway 1mg Immunotherapy Drug Antibody Conjugate Topoisomerase I, TROP2 No 2025 Sep 8, 2025 In Use
Q0180 Dolasetron Mesylate Anzemet 100 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Apr 1, 1998 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
Q5158 Denosumab-bnht Bomyntra, Conexxence 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
NA lenvatinib Lenvima 4 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET Yes 2015 In Use
S0088 Imatinib mesylate Gleevec 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2001 Jan 1, 2002 In Use
NA Pomalidomide Pomalyst 1 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
NA Prednisolone Tebutate Hydeltra-TBA, Norpred TBA, Predalone T.B.A., Predate TBA, Predcor TBA, Prednisol TBA, Prednisolone TBA, TBA Pred 20 mg Hormonal Therapy Adrenal Glucocorticoid Corticosteroid No 1956 2003 In Use
C1086 Temozolomide Temodar 5 mg Chemotherapy Alkylating Agent Tetrazine Yes 1999 Jan 1, 2010 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.